China's Biotech Industry

Chinese scientists use allergy-like immune response for cancer therapy​

Instead of allowing mast cells to respond to allergens, the team reprogrammed them using IgE antibodies that recognize proteins found on tumor cells.

When these customized mast cells are injected into the bloodstream, they travel to tumors and unleash sudden bursts of inflammation upon encountering their specific cancer target.

Click to expand...

Sensitized mast cells for targeted drug delivery and augmented cancer immunotherapy​

Click to expand...

supercat said:

Another one goes to China - SCMP headline and video summary below:

Click to expand...

Cambridge University ex-vice-chancellor Nigel Slater joins China’s biotech revolution​

Veteran academic to collaborate with Chinese scientists to develop next-gen cancer therapies using vaccine tech for tumour immunotherapy

Click to expand...

NeuroXess Achieves Milestone With China’s First Battery-Integrated Brain Chip Implant
...
Earlier generations of BCI products required battery modules to remain outside the skull and relied on external devices for power. NeuroXess’ product fully implants the core module containing the battery inside the body, integrating wireless power supply and wireless data transmission, allowing patients to dispense entirely with external equipment and fundamentally eliminating infection risks at the physical level, said Tao Hu, founder and chief scientist of NeuroXess.

The company has also placed the battery module subcutaneously in the chest and optimized the architecture of deep brain stimulation technology to move heat-generating components away from the brain, further enhancing system safety, Tao added.

Click to expand...

GE Healthcare's only system-level MRI research and innovation center outside the United States has been established in Tianjin, China.​

China’s Changchun High-Tech Gains After Licensing Innovative Hyperthyroidism Drug to US Yarrow
GS-098 is a clinical-stage, first-in-class, humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor for the treatment of Graves’ disease and thyroid eye disease. In August last year, it obtained regulatory approval for clinical trials for thyroid-associated orbitopathy in China and the United States. In October, it was approved for clinical trials for GD in China.

Click to expand...

We analyzed more than 17,000 different drugs, biologics, and biologicals to identify the organizations responsible for the development of each. We then located these organizations’ headquarters and classified them as public or private-sector entities. We postulated that China’s contributions to drug discovery might be rising, perhaps ranking equal to long-standing pharmaceutical pioneers such as Switzerland or Japan. Reality was quite different.

When national contributions were compared on an annual basis, China had not merely surpassed the collective output of Europe and the rest of Asia, but gained parity with the United States. This outcome is all the more remarkable as the growth occurred almost entirely over the past decade. As an example, China’s output in terms of new drug discovery had increased from about 30 new medicines in 2013 to more than 400 a decade later. Output by American sources has remained comparatively flat since 2018, while China’s contributions nearly tripled in that same period.

Click to expand...